IP that matters: behind Orexo’s milestone patent win at the US court (Stockholm)

IP that matters: behind Orexo’s milestone patent win at the US court (Stockholm)
date
October 15, 2025
TIme
17:30 - 20:00 CEST
Address

Berns Hotel, Stockholm

The panel discussion will unpack Orexo’s decisive US patent litigation victory over Sun Pharma, a milestone case that underscores the critical value of a robust intellectual property strategy.

This case offers important insights for innovators, pharma companies, biotech firms, and IP professionals facing aggressive generic competition.

Why attend

Learn from the experts - Hear from those who lived it:

  • Orexo – on the effective use of IP to meet its business objectives, safeguarding life‑changing treatments for opioid dependence;
  • Steptoe - US litigators who brought and successfully argued the case before the court; and
  • Potter Clarkson – Orexo’s patent attorneys who had a key, central role in preparing the ground for that success

Understand the strategy - See how targeted IP planning can protect market share and innovation pipelines

Take away real‑world lessons - Practical insights on resilience, litigation strategy, and long‑term protection of breakthrough work

Event format

  • Panel discussion with candid, behind‑the‑scenes perspectives
  • Interactive Q&A session - get your questions answered by the case’s key players
  • Networking and refreshments to connect with peers in pharma, biotech, and IP law

Who should attend

  • Pharma and biotech executives
  • IP lawyers, patent attorneys, and in‑house counsel
  • R&D and innovation leaders
  • Investors and stakeholders in healthcare innovation

Reserve your place today - spaces are limited, and this is a unique opportunity to hear the inside story of a case that’s shaping IP strategy in life sciences.

Latest News

Potter Clarkson ranked in Managing IP's IP STARS 2026

Potter Clarkson ranked in Managing IP's IP STARS 2026

Combination therapies: IP considerations for synergistic biologic products

Combination therapies: IP considerations for synergistic biologic products

Perfect storm - four drivers behind the mRNA litigation wave

Perfect storm - four drivers behind the mRNA litigation wave

Patent landscape and freedom-to-operate analysis for RNA-based therapies: identifying IP risks early

Patent landscape and freedom-to-operate analysis for RNA-based therapies: identifying IP risks early

Kodak v FujiFilm: the Court of Appeal confirms UPC’s long-arm jurisdiction

Kodak v FujiFilm: the Court of Appeal confirms UPC’s long-arm jurisdiction

Comparing EPC Article 53(a) and US patent law in gene editing ethics

Comparing EPC Article 53(a) and US patent law in gene editing ethics

EPO Board of Appeal refers claim interpretation and added matter questions

EPO Board of Appeal refers claim interpretation and added matter questions

Creating an effective IP strategy for CAR-T

Creating an effective IP strategy for CAR-T

See All News